These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26023082)

  • 1. β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer.
    San Millán C; Soldevilla B; Martín P; Gil-Calderón B; Compte M; Pérez-Sacristán B; Donoso E; Peña C; Romero J; Granado-Lorencio F; Bonilla F; Domínguez G
    Clin Cancer Res; 2015 Oct; 21(19):4398-409. PubMed ID: 26023082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo.
    Liu Y; Xiao E; Yuan L; Li G
    DNA Cell Biol; 2014 Jul; 33(7):418-25. PubMed ID: 24720675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ΔNp73β on cisplatin treatment in colon cancer cells.
    Lööf J; Pfeifer D; Ding Z; Sun XF; Zhang H
    Mol Carcinog; 2012 Aug; 51(8):628-35. PubMed ID: 21837762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells.
    Rana S; Gupta K; Gomez J; Matsuyama S; Chakrabarti A; Agarwal ML; Agarwal A; Agarwal MK; Wald DN
    FASEB J; 2010 Jun; 24(6):2126-34. PubMed ID: 20133503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo.
    Liu X; Xu J; Wang S; Yu X; Kou B; Chai M; Zang Y; Chen D
    Int J Oncol; 2017 Oct; 51(4):1291-1299. PubMed ID: 28902369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma.
    Das R; Bhattacharya K; Sarkar S; Samanta SK; Pal BC; Mandal C
    Apoptosis; 2014 Jan; 19(1):149-64. PubMed ID: 24052409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance of mitochondrial p53 to dominant inhibition.
    Heyne K; Schmitt K; Mueller D; Armbruester V; Mestres P; Roemer K
    Mol Cancer; 2008 Jun; 7():54. PubMed ID: 18547443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
    Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
    Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients.
    Soldevilla B; Díaz R; Silva J; Campos-Martín Y; Muñoz C; García V; García JM; Peña C; Herrera M; Rodriguez M; Gómez I; Mohamed N; Marques MM; Bonilla F; Domínguez G
    Clin Cancer Res; 2011 Sep; 17(18):6029-39. PubMed ID: 21807636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73.
    Lu C; Wang W; El-Deiry WS
    Cancer Biol Ther; 2008 Dec; 7(12):2039-46. PubMed ID: 19106635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
    Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
    Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.
    Hua H; Chen W; Shen L; Sheng Q; Teng L
    Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):773-9. PubMed ID: 23786838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs.
    Sabatino MA; Previdi S; Broggini M
    Int J Cancer; 2007 Feb; 120(3):506-13. PubMed ID: 17096333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells.
    Liu HF; Hu HC; Chao JI
    Chem Biol Interact; 2010 Dec; 188(3):535-45. PubMed ID: 20708607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.
    Ma Y; Yu WD; Hershberger PA; Flynn G; Kong RX; Trump DL; Johnson CS
    Mol Cancer Ther; 2008 Sep; 7(9):3047-55. PubMed ID: 18790784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
    Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
    Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells.
    Vondálová Blanářová O; Jelínková I; Hyršlová Vaculová A; Sova P; Hofmanová J; Kozubík A
    Cell Prolif; 2013 Dec; 46(6):665-76. PubMed ID: 24118195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.